Navigation Links
University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
Date:12/8/2010

SALT LAKE CITY, Dec. 8, 2010 /PRNewswire/ -- Navigen Pharmaceuticals, Inc. today announced that it has been awarded a new four year contract from the Department of Defense Program, Transformational Medical Technologies (TMT) for the development of Navigen's protein therapeutic, Slit2N, for the treatment of viral hemorrhagic fevers (resulting from exposure to agents such as Ebola or Marburg virus) and anthrax infection.  Navigen Pharmaceuticals, Inc. may receive up to $21.5 million in support of development efforts under this new Defense Threat Reduction Agency (DTRA) contract HDTRA1-10-C-0054.

The Slit2N technology originated in the laboratory of Dean Li, M.D., Ph.D., director of the University of Utah's Molecular Medicine Program, and is licensed from the University by Navigen.  The University of Utah School of Medicine's Molecular Medicine Program is a unique cadre of physician-scientists and basic science researchers collaborating to find solutions to important problems in clinical medicine.  In March of 2010, Li and colleagues in the Molecular Medicine Program published a study in Science Translational Medicine showing that Slit2N controlled the otherwise pathologic effects of the inflammatory response to virulent influenza, sepsis, and other potentially deadly infections while allowing the body's immune system to fight the underlying infection.  Although inflammation is a healthy part of the body's immune response, when left unchecked it weakens blood vessels and causes them to leak.  In the most extreme cases, this vascular leak results in non-cardiogenic shock and organ failure.  Li found that Slit2N can prevent the negative effects of inflammation and stabilize blood vessels.  The discovery raised the possibility that broad-range therapies could be developed to fight both viral and bacterial infections, such as pandemic flu, sepsis, and even human-made biological agents.

"This is the kind of discov
'/>"/>

SOURCE Navigen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
2. University of Pennsylvania scientists move optical computing closer to reality
3. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
4. University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia
5. Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
6. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
7. George Washington University Hospital Purchases Orthocrats TraumaCad(TM) for Orthopedic Preoperative Planning
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University
10. Stuart Parkin first distinguished professor at Eindhoven University of Technology
11. McMaster University unveils worlds most advanced microscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... by Rice University has brought a wealth of new information ... The current issue of the American Chemical Society journal ... the Rice lab of chemist Bruce Weisman to understand how ... in this case, the light they emit at near-infrared ...
... Realty Trust, Inc. (NYSE: BMR ) today announced ... ended December 31, 2011 after the market closes on Wednesday, ... and Chief Executive Officer, Kent Griffin, President, Matt McDevitt, Executive ... host an investor conference call at 10:00 a.m. Pacific Time ...
... DURHAM, N.C., Jan. 31, 2012  Argos Therapeutics Inc., ... immune monitoring analysis of AGS-003-006, a Phase 2 ... with sunitinib in patients with advanced renal cell ... correlation between anti-tumor memory T cell responses and ...
Cached Biology Technology:Perfect nanotubes shine brightest 2BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... are two root causes of a type of diabetes associated ... a clinical trial, may guide development of new treatments or ... Almost half of patients with CF will develop diabetes by ... their teens. In addition to the health problems caused by ...
... CORVALLIS, Ore. Diatoms, tiny marine life forms that ... biofuel production from algae truly cost-effective because they ... biomedical products and even health foods. Engineers at ... the envelope a bit. But it,s not science fiction ...
... and pregnant, your baby isn,t destined to a life of ... online in The FASEB Journal . In ... fat intake during pregnancy to a moderate level is enough ... they found that a protein called "SIRT1" rewrites a developing ...
Cached Biology News:Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: